Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Nextcure Inc (NXTC)

Nextcure Inc (NXTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,137
  • Shares Outstanding, K 27,747
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,390 K
  • 60-Month Beta -0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade NXTC with:

Options Overview Details

View History
  • Implied Volatility 252.55% ( +22.51%)
  • Historical Volatility 52.86%
  • IV Percentile 99%
  • IV Rank 35.31%
  • IV High 594.40% on 09/22/22
  • IV Low 65.95% on 07/08/22
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 129
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 9,632
  • Open Int (30-Day) 10,406

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.60
  • Number of Estimates 4
  • High Estimate -0.42
  • Low Estimate -0.73
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.66 +5.64%
on 09/27/22
4.36 -35.55%
on 08/30/22
-1.46 (-34.19%)
since 08/29/22
3-Month
2.66 +5.64%
on 09/27/22
5.27 -46.68%
on 08/16/22
-2.03 (-41.94%)
since 06/29/22
52-Week
2.66 +5.64%
on 09/27/22
9.18 -69.39%
on 10/15/21
-4.02 (-58.86%)
since 09/29/21

Most Recent Stories

More News
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium

BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)
NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)
Chau Khuong Joins Catalio Capital Management as General Partner

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined...

FUSN : 2.96 (-1.99%)
GKOS : 53.53 (+0.98%)
NTLA : 55.29 (-5.71%)
ICPT : 16.41 (-3.64%)
INSP : 177.12 (-1.69%)
NXTC : 2.81 (+1.08%)
PIRS : 1.1500 (unch)
Oversold Conditions For NextCure (NXTC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

NXTC : 2.81 (+1.08%)
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6 million that is...

NXTC : 2.81 (+1.08%)
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 2.81 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland....

See More

Key Turning Points

3rd Resistance Point 2.98
2nd Resistance Point 2.90
1st Resistance Point 2.86
Last Price 2.81
1st Support Level 2.74
2nd Support Level 2.66
3rd Support Level 2.62

See More

52-Week High 9.18
Fibonacci 61.8% 6.69
Fibonacci 50% 5.92
Fibonacci 38.2% 5.15
Last Price 2.81
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar